

Reference Number: FOI202223/199
From: Private Individual
Date: 26 August 2022
Subject: Treatment of metastatic non-small cell lung cancer

Q1 In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- a. Afatinib
- b. Alectinib
- c. Atezolizumab monotherapy
- d. Atezolizumab in combination
- e. Bevacizumab
- f. Brigatinib
- g. Capmatenib
- h. Ceritinib
- i. Crizotinib
- j. Dacomitinib
- k. Dabrafenib with Trametinib
- l. Docetaxel monotherapy
- m. Durvalumab
- n. Erlotinib
- o. Gefitinib
- p. Gemcitabine
- q. Nintedanib with Docetaxel
- r. Nivolumab
- s. Osimertinib
- t. Paclitaxel
- u. Pembrolizumab monotherapy
- v. Pembrolizumab in combination
- w. Pemetrexed with Carboplatin/Cisplatin
- x. Tepotinib
- y. Vinorelbine with Cisplatin/Carboplatin
- z. Any other SACT
- aa. Palliative care only

- A1**
- a. Zero
 - b. Zero
 - c. Zero
 - d. Zero
 - e. Zero
 - f. Zero
 - g. Zero
 - h. Zero
 - i. Zero
 - j. Zero

- k. Zero
- l. Zero
- m. Zero
- n. Zero
- o. Zero
- p. Zero
- q. Zero
- r. Zero
- s. Zero
- t. Zero
- u. Zero
- v. Zero
- w. Zero
- x. Zero
- y. Zero
- z. Zero

- aa. Information not held – In the majority of cases the Trust refers palliative oncology cases to Clatterbridge Centre for Oncology.

We advise directing oncology requests to them:

<https://www.clatterbridgecc.nhs.uk/about-centre/access-to-information/freedom-information-foi>